Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press
Series of Journals
Center for Evidence-Based and Translational Medicine of Wuhan University
The title
The title
The keywords
The author
Submit
Home
About us
Journal Introduction
Chief Editor
Editorial Committee
Author Center
Submission Guide
Assignment Agreement
Articles
Subscribe
Copyright
Contact us
Draft submission system
Author login
Author register
Reviewer login
Editor login
Home
Results
The title
The title
The keywords
The author
A total of
6
result was found. Results that relate to
Pharmacoeconomic
黄葵胶囊对比氯沙坦钾片治疗IgA肾病的药物经济学评价
Liang-Wen GOU
Zhao-Ting GUO
Qiong LUO
Nan YANG
Ming HU
DOI:10.19960/j.issn.1005-0698.202301001
Huangkui capsule
Losartan potassium tablets
Chronic kidney disease
Pharmacoeconomic
s
Cost-utility analysis
Details
Download
Mobile
阿扎胞苷与地西他滨治疗骨髓增生异常综合征的成本-效用分析
La-Ji DANZENG
Yong-Gong YANG
Si-Liang WANG
Meng-Ying LIU
DOI:10.19960/j.issn.1005-0698.202312007
Azacitidine
Decitabine
Myelodysplastic syndrome
Markov model
Cost-utility analysis
Pharmacoeconomic
s
Details
Download
Mobile
百令胶囊联合西医常规治疗糖尿病肾病的药物经济学研究
HE Yumei
LI Wei
ZHU He
HAN Sheng
DOI:10.12173/j.issn.1005-0698.202401013
Bailing capsules
Diabetic kidney disease
Meta-analysis
Cost- effectiveness analysis
Pharmacoeconomic
s
Details
Download
Mobile
基于Markov模型的胰高血糖素样肽1受体激动剂联合二甲双胍治疗2型糖尿病药物经济学评价
YU Tian
LIU Shaohua
WEI Anhua
GUO Jieru
ZHANG Chengliang
LIU Dong
LIU Zhelong
DOI:10.12173/j.issn.1005-0698.202304014
Glucagon-like peptide-1 receptor agonist
Metformin
Type 2 diabetes mellitus
Cost-utility
Markov model
Pharmacoeconomic
s
Details
Download
Mobile
氟替美维吸入粉雾剂治疗慢性阻塞性肺疾病的药物经济学评价
DING Xueru
LIU Huimin
HE Xiaodong
LI Hua
LI Zhihao
DOI:10.12173/j.issn.1005-0698.202404016
Fluticasone furoate/umeclidinium/vilanterol
Chronic obstructive pulmonary disease
Markov model
Cost-utility analysis
Pharmacoeconomic
Details
Download
Mobile
帕博利珠单抗联合化疗治疗晚期恶性胸膜间皮瘤的成本-效用分析
HU Yunjia
ZOU Keqing
HOU Yanhong
DOI:10.12173/j.issn.1005-0698.202407011
Pembrolizumab
Chemotherapy
Advanced malignant pleural mesothelioma
Partitioned survival model
Cost-utility analysis
Pharmacoeconomic
evaluation
Details
Download
Mobile